Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
ALK-positive anaplastic large cell lymphoma Indication Strategy Report 2026: ALK, Trials and Deals
24 July 2026
2026 ALK-positive anaplastic large cell lymphoma strategy: epidemiology, ALK biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Embryonal tumor with multilayered rosettes Indication Strategy Report 2026: C19MC, Trials and Deals
24 July 2026
2026 Embryonal tumor with multilayered rosettes strategy: epidemiology, C19MC biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Intracranial germinoma Indication Strategy Report 2026: KIT, Trials and Deals
24 July 2026
2026 Intracranial germinoma strategy: epidemiology, KIT biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Pineoblastoma Indication Strategy Report 2026: CRX, Trials and Deals
24 July 2026
2026 Pineoblastoma strategy: epidemiology, CRX biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Diffuse hemispheric glioma H3 G34-mutant Indication Strategy Report 2026: H3F3A, Trials and Deals
24 July 2026
2026 Diffuse hemispheric glioma H3 G34-mutant strategy: epidemiology, H3F3A biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Astrocytoma Indication Strategy Report 2026: IDH1, Trials and Deals
24 July 2026
2026 Astrocytoma strategy: epidemiology, IDH1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Oligodendroglioma Indication Strategy Report 2026: IDH1, Trials and Deals
24 July 2026
2026 Oligodendroglioma strategy: epidemiology, IDH1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Leptomeningeal metastasis Indication Strategy Report 2026: HER2, Trials and Deals
24 July 2026
2026 Leptomeningeal metastasis strategy: epidemiology, HER2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Pilocytic astrocytoma Indication Strategy Report 2026: BRAF, Trials and Deals
24 July 2026
2026 Pilocytic astrocytoma strategy: epidemiology, BRAF biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Primary central nervous system lymphoma Indication Strategy Report 2026: BTK, Trials and Deals
24 July 2026
2026 Primary central nervous system lymphoma strategy: epidemiology, BTK biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Choriocarcinoma Indication Strategy Report 2026: hCG, Trials and Deals
24 July 2026
2026 Choriocarcinoma strategy: epidemiology, hCG biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Uterine clear cell carcinoma Indication Strategy Report 2026: ARID1A, Trials and Deals
24 July 2026
2026 Uterine clear cell carcinoma strategy: epidemiology, ARID1A biology, clinical competition, recent deals, unmet need and market attractiveness.